John Che

[Radek Nowak @RPNowak]

Introducing HiBiT-SpyTag - A Minimal Tag for Covalent Protein Capture and Degrader Development.
Developed at the CPD with @BLZerf6 @LynJonesChemBio and the team! A thread 1/N
https://t.co/jbBm1JmkRo

[Ed Chouchani @echouchani]

Very excited to share our study published today in @nchembio. We developed a first-in-class covalent inhibitor for creatine kinases, using chemoproteomics to target a conserved active site cysteine.
https://t.co/opWjlNWXCD

[Lyn Jones @LynJonesChemBio]

We developed ternary complex structural knowledge to elucidate IKZF1 and GSPT1 structure-degradation relationships that we hope will help the future design of cereblon modulators - just published @rsc_medchem #TargetedProteinDegradation https://t.co/niojydztNb

[John Che @generadar]

@jaybradner Looks like off target binding

[Andrew White 🐦‍⬛ @andrewwhite01]

Packaged our algorithm to design binding peptides into a simple colab. Enter a protein sequence, indicate where you want the peptide to bind, and in a few minutes you'll have a peptide predicted to tightly bind via AlphaFold + Bayesian Optimization. 1/2

https://t.co/MvoXmnUHvK

[John Che @generadar]

good read https://t.co/5B6P8gMoI9

[Covalent Modifiers @CovalentMod]

Covalent Disruptor of YAP-TEAD Association Suppresses Defective Hippo Signaling https://t.co/Fx8ldD1xzU

[Lyn Jones @LynJonesChemBio]

Just accepted @rsc_chembio - we synthetically modified the surface of cereblon through site-selective histidine covalent targeting using sulfonyl exchange chemistry. A great effort from the team! #TargetedProteinDegradation https://t.co/8Edt0MM8b7

[John Che @generadar]

https://t.co/4v1OR6jGWP

[soria @jsoriamd]

A review on the development of 3rd G EGFR & ALK inhibitors, predominant mechanisms of resistance, & approaches to tackling resistance in the clinic.
https://t.co/HPNlvONldu

[John Che @generadar]

This is pretty awesome https://t.co/HENn0Hk4pT

[John Che @generadar]

Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors | Nature Biotechnology https://t.co/OrqOkLtQcp

[Craig Crews @CraigMCrews]

Ever wanted to quickly make a #PROTAC degrader of a #TranscriptionFactor? Check out our latest generation of TRAFTACs- just a TF binding sequence dsDNA oligo coupled to our VHL ligand. PoC studies degraded Myc and #brachyury. https://t.co/X1TbzwP3qu

[John Che @generadar]

https://t.co/CAz3NF30g8

[John Che @generadar]

An exciting opportunity at the center for protein degradation, join us to explore the amazing world of targeted protein degradation https://t.co/WLoyY6KDw3

[John Che @generadar]

The secret lives of cells — as never seen before https://t.co/JQjcnuTcBx

[NatureRevClinOncol @NatRevClinOncol]

Now online, new Review from @DralexGva @VivekSubbiah @Al3ssandroRusso @gbanna74 @UmbertoMalapel1 @ChristianRolfo and @Alfdoc2 on EGFR and HER2 exon 20 insertions in solid tumours, such a timely topic with the recent approval of mobocertinib https://t.co/P28p494JlN

[John Che @generadar]

@demishassabis @Nature Maybe you could find a sequence that folds into human shape :)

[Feng Zhang @zhangf]

We are really excited to share our work on a new modular RNA delivery technology called SEND, built from endogenous components found in the mammalian genome. @ScienceMagazine https://t.co/0HRvKkDAFV

[John Che @generadar]

https://t.co/PzBAFp58Li